Who
Richard C. Henriques Jr.
Director
Company insider
Files Form 4 as: Director, Cabaletta Bio; Director, Arbutus Biopharma; V.P., Controller, Merck & Co.
In numbers
- Trades disclosed
- 33
- Buys
- 1
- Sells
- 1
- Bought
- $6,950
- Sold
- $857K
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 6 Feb 2006
- Last trade
- 9 Jun 2026
- Last filed
- 10 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 10 Jun 2026 | CABA Cabaletta Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | CABA Cabaletta Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 9 Jun 2025filed 9 Jun 2025 | CABA Cabaletta Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 19 May 2025filed 19 May 2025 | CABA Cabaletta Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —46,428 at $0.00 | filing |
| 19 May 2025filed 19 May 2025 | CABA Cabaletta Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —46,428 at $0.00 | filing |
| 19 May 2025filed 19 May 2025 | CABA Cabaletta Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —22,000 at $0.00 | filing |
| 19 May 2025filed 19 May 2025 | CABA Cabaletta Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 19 May 2025filed 19 May 2025 | CABA Cabaletta Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —22,000 at $0.00 | filing |
| 19 May 2025filed 19 May 2025 | CABA Cabaletta Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 19 May 2025filed 19 May 2025 | CABA Cabaletta Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —22,000 at $0.00 | filing |
| 19 May 2025filed 19 May 2025 | CABA Cabaletta Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 3 Jun 2024filed 4 Jun 2024 | CABA Cabaletta Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 23 May 2024filed 24 May 2024 | ABUS Arbutus Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,000 at $0.00 | filing |
| 1 Jun 2023filed 2 Jun 2023 | CABA Cabaletta Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 24 May 2023filed 26 May 2023 | ABUS Arbutus Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 1 Jun 2022filed 3 Jun 2022 | CABA Cabaletta Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 25 May 2022filed 26 May 2022 | ABUS Arbutus Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,000 at $0.00 | filing |
| 3 Jun 2021filed 7 Jun 2021 | ABUS Arbutus Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 1 Jun 2021filed 3 Jun 2021 | CABA Cabaletta Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 28 May 2020filed 1 Jun 2020 | ABUS Arbutus Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
News
Contrasting Arbutus Biopharma (NASDAQ:ABUS) and Evaxion A/S (NASDAQ:EVAX)ABUS · tickerreport.com · 18 Oct 2026Reviewing Arbutus Biopharma (NASDAQ:ABUS) & Prelude Therapeutics (NASDAQ:PRLD)ABUS · tickerreport.com · 17 Oct 2026Arbutus Biopharma (NASDAQ:ABUS) vs. Immunome (NASDAQ:IMNM) Financial ComparisonABUS · themarketsdaily.com · 12 Oct 2026
0 headlines in the last 90 days name Richard C. Henriques Jr.; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.
Sectors
Related people
Nobody else traded the same names lately.